Journal
JOURNAL OF MEDICINAL CHEMISTRY
Volume 55, Issue 17, Pages 7417-7424Publisher
AMER CHEMICAL SOC
DOI: 10.1021/jm300841n
Keywords
-
Categories
Funding
- Ministry of Higher Education, Science and Technology of the Republic of Slovenia
- Slovenian Research Agency [J3-4135]
- NIH grant [1R01-CA90744, P30-ES013508]
- Prostate Cancer Foundation
Ask authors/readers for more resources
Human aldo-keto reductases 1C1-1C4 (AKR1C1-AKR1C4) function in vivo as 3-keto-, 17-keto-, and 20-ketosteroid reductases and regulate the activity of androgens, estrogens, and progesterone and the occupancy and transactivation of their corresponding receptors. Aberrant expression and action of AKR1C enzymes can lead to different pathophysiological conditions. AKR1C enzymes thus represent important targets for development of new drugs. We performed a virtual high-throughput screen of a fragment library that was followed by biochemical evaluation on AKR1C1-AKR1C4 enzymes. Twenty-four structurally diverse compounds were discovered with low mu M K-i values for AKR1C1, AKR1C3, or both. Two structural series included the salicylates and the N-phenylanthranilic acids, and additionally a series of inhibitors with completely novel scaffolds was discovered. Two of the best selective AKR1C3 inhibitors had K-i values of 0.1 and 2.7 mu M exceeding expected activity for fragments. The compounds identified represent an excellent starting point for further hit-to-lead development.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available